The stock of Gritstone Bio Inc (GRTS) has seen a 18.36% increase in the past week, with a -6.99% drop in the past month, and a -58.14% decrease in the past quarter. The volatility ratio for the week is 9.05%, and the volatility levels for the past 30 days are at 10.32% for GRTS. The simple moving average for the last 20 days is 15.78% for GRTS stock, with a simple moving average of -48.71% for the last 200 days.
Is It Worth Investing in Gritstone Bio Inc (NASDAQ: GRTS) Right Now?
The 36-month beta value for GRTS is also noteworthy at 0.60. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for GRTS is 97.92M, and at present, short sellers hold a 13.07% of that float. The average trading volume of GRTS on May 06, 2024 was 2.77M shares.
GRTS) stock’s latest price update
The stock of Gritstone Bio Inc (NASDAQ: GRTS) has increased by 10.66 when compared to last closing price of 0.87. Despite this, the company has experienced a 18.36% gain in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-05-02 that Gritstone bio (GRTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts’ Opinion of GRTS
Many brokerage firms have already submitted their reports for GRTS stocks, with JMP Securities repeating the rating for GRTS by listing it as a “Mkt Outperform.” The predicted price for GRTS in the upcoming period, according to JMP Securities is $4 based on the research report published on February 28, 2024 of the current year 2024.
B. Riley Securities gave a rating of “Buy” to GRTS, setting the target price at $8 in the report published on March 28th of the previous year.
GRTS Trading at -44.76% from the 50-Day Moving Average
After a stumble in the market that brought GRTS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.09% of loss for the given period.
Volatility was left at 10.32%, however, over the last 30 days, the volatility rate increased by 9.05%, as shares sank -0.77% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -53.49% lower at present.
During the last 5 trading sessions, GRTS rose by +18.36%, which changed the moving average for the period of 200-days by -57.02% in comparison to the 20-day moving average, which settled at $0.8311. In addition, Gritstone Bio Inc saw -52.81% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GRTS starting from Economides Vassiliki, who purchase 12,000 shares at the price of $1.90 back on May 23 ’23. After this action, Economides Vassiliki now owns 214,058 shares of Gritstone Bio Inc, valued at $22,829 using the latest closing price.
Stock Fundamentals for GRTS
Current profitability levels for the company are sitting at:
- -59.14 for the present operating margin
- -13.21 for the gross margin
The net margin for Gritstone Bio Inc stands at -54.61. The total capital return value is set at -1.0. Equity return is now at value -124.41, with -66.18 for asset returns.
Based on Gritstone Bio Inc (GRTS), the company’s capital structure generated 0.48 points at debt to capital in total, while cash flow to debt ratio is standing at -2.9. The debt to equity ratio resting at 0.91. The interest coverage ratio of the stock is -72.94.
Currently, EBITDA for the company is -147.04 million with net debt to EBITDA at -0.28. When we switch over and look at the enterprise to sales, we see a ratio of 56.24. The receivables turnover for the company is 10.98for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.20.
Conclusion
In summary, Gritstone Bio Inc (GRTS) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
